CI

At a glance

ClinicalIndex Comparison Record
Phase 3Active· 371 enrolled / 371 target
Drug / intervention
BMS-663068 +1 moredrug
Likely dose
600 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02362503
NCT02362503Phase 3ActiveUpdate Overdue (2.7/mo)Completion was 118mo ago
CompareCT.gov

A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)

ViiV Healthcare·interventional·Posted Feb 13, 2015·Updated Jun 17, 2026

In Brief

A Phase 3 clinical trial evaluating BMS-663068 and Placebo for HIV Infections. Active but no longer recruiting, targeting 371 participants across 139 sites in 25 countries.

Signals

Enrollment appears stalled

Detailed Summary

The purpose of this study is to determine whether the BMS Attachment Inhibitor (BMS-663068) is effective in the treatment of heavily treatment experienced HIV-1 patients with multi-drug resistance.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesArgentina, Australia, Belgium, Brazil, Canada, Chile, Colombia, France, Germany, Greece, Ireland, Italy, Mexico, Netherlands, Peru, Poland, Portugal, Puerto Rico, Romania, Russia, South Africa, Spain, Taiwan, United Kingdom, United States
Collaborators--

Timeline

Phase 3Active
2015201620172018201920202021202220232024202520262027
First PostedFeb 13, 2015
Enrollment StartFeb 23, 2015
Primary CompletionAug 18, 2016
Study CompletionJan 28, 2027
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 11.4 years ago

Arms & Interventions

A1: BMS-663068experimental

Phase 1: BMS-663068 600 mg tablets orally twice daily for 8 days. Phase 2: BMS-663068 600 mg tablets orally twice daily for 48 weeks or longer.

Drug: BMS-663068
B1: Placebo + BMS-663068active_comparator

Phase 1: Placebo twice daily for 8 days. Phase 2: BMS-663068 600 mg tablets orally twice daily for 48 weeks or longer.

Drug: BMS-663068Other: Placebo
BMS-663068experimental

BMS-663068 600 mg tablets orally twice daily for 48 weeks or longer.

Drug: BMS-663068

Interventions

BMS-663068drug

BMS-663068

Placeboother

Placebo